Functional and Pharmacological Evaluation of a Novel SCN2A Variant Linked to Early-onset Epilepsy

Scott K. Adney, M.D., Ph.D., 1 John J. Millichap, M.D.,2,3 Jean-Marc DeKeyser,4 Tatiana Abramova,4 Christopher H. Thompson, Ph.D.,4 and Alfred L. George, Jr., M.D.4

1Department of Neurology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611 USA
2Department of Pediatrics, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611 USA
3Ann and Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL 60611 USA
4Department of Pharmacology, Feinberg School of Medicine, Northwestern University, Chicago, IL 60611 USA

Running Title Function and pharmacology of novel SCN2A variant

Abstract Word Count 222

Word Count 3326

Key words sodium channel, Na\(_{\text{v}}\)1.2, epilepsy, carbamazepine

Correspondence: Alfred L. George, Jr., M.D.
Department of Pharmacology
Northwestern University Feinberg School of Medicine
Searle 8-510
320 E. Superior St.
Chicago, IL 60611
312-503-4893
al.george@northwestern.edu
ABSTRACT

Objective
We identified a novel de novo SCN2A variant (M1879T) associated with infantile-onset epilepsy that responded dramatically to sodium channel blocker antiepileptic drugs. We analyzed the functional and pharmacological consequences of this variant to establish pathogenicity, and to correlate genotype with phenotype and clinical drug response.

Methods
The clinical and genetic features of an infant boy with epilepsy are presented. We investigated the effect of the variant using heterologously expressed recombinant human Na\textsubscript{v}1.2 channels. We performed whole-cell patch clamp recording to determine the functional consequences and response to carbamazepine.

Results
The M1879T variant caused disturbances in channel inactivation including substantially depolarized voltage-dependence of inactivation, slower time course of inactivation, and enhanced resurgent current that collectively represent a gain-of-function. Carbamazepine partially normalized the voltage-dependence of inactivation and produced use-dependent block of the variant channel at high pulsing frequencies. Carbamazepine also suppresses resurgent current conducted by M1879T channels, but this effect was explained primarily by reducing the peak transient current. Molecular modeling suggests that the M1879T variant disrupts contacts with nearby residues in the C-terminal domain of the channel.

Interpretation
Our study demonstrates the value of conducting functional analyses of SCN2A variants of unknown significance to establish pathogenicity and genotype-phenotype correlations. We also show concordance of in vitro pharmacology using heterologous cells with the drug response observed clinically in a case of SCN2A-associated epilepsy.
INTRODUCTION

Variants in the SCN2A gene are associated with a range of childhood epilepsies differing in severity with or without accompanying neurodevelopmental delay.\(^1\)\(^2\) Clinical phenotypes include benign infantile seizures, developmental epileptic encephalopathy, West syndrome, and Ohtahara syndrome. SCN2A encodes the pore-forming subunit of the voltage-gated sodium channel Na\(_{v}\)1.2. Gain-of-function variants, which result in greater Na\(_{v}\)1.2 activity than normal, are associated with neonatal and infantile-onset epilepsy (onset before 3 months of age).\(^3\) By contrast, loss-of-function variants are associated with later-onset epilepsy with more prominent neurodevelopmental delay as well as autism spectrum disorder.\(^4\) More widespread genetic testing of children with epilepsy has resulted in an explosion of new SCN2A variants,\(^5\) yet the functional consequences and clear genotype-phenotype relationships have not been determined for most variants.

The majority of Na\(_{v}\)1.2 channels are concentrated in the axon initial segment (AIS) of cortical excitatory neurons. During early development, Na\(_{v}\)1.2 predominates throughout the AIS, acting as an action potential initiator and summing somatodendritic inputs. As neurons mature, Na\(_{v}\)1.6 (encoded by SCN8A) replaces Na\(_{v}\)1.2 in the more distal segments of the AIS. Later in development, Na\(_{v}\)1.2 contributes to the back propagation of action potentials into the somatodendritic compartment of excitatory neurons.\(^6\)\(^8\) Gain-of-function variants in SCN2A are thought to cause early-onset epilepsy by promoting excitability of cortical neurons during the developmental stage when Na\(_{v}\)1.2 predominates in the AIS.\(^9\) Clinical studies suggest that some infantile-onset epilepsies due to gain-of-function variants are responsive to treatment with anti-seizure drugs (ASDs) having a principal mechanism of action to block sodium channels, albeit in a nonselective manner.\(^10\)
Here we report a case of infantile-onset epilepsy associated with a novel SCN2A variant (M1879T) of uncertain significance combined with extensive functional and pharmacological studies of the variant sodium channel. Our findings reveal a novel constellation of functional abnormalities associated with infantile-onset epilepsy, and provide a demonstration that \textit{in vitro} pharmacological properties of a variant sodium channel correlate with the clinical response to a specific drug.
MATERIALS AND METHODS

Study Participant

The patient was recruited to study #2015-738 approved by the Institutional review Board of Ann & Robert H. Lurie Children’s Hospital of Chicago. Following informed consent, data was collected by parental report through a REDCap database questionnaire and review of medical records.

Mutagenesis and heterologous expression of Na\textsubscript{v}1.2

The open reading frame of human Na\textsubscript{v}1.2 was subcloned into a custom pCMV-IRES-mScarlet vector. The M1879T mutant channel was constructed using site-directed mutagenesis PCR (Forward primer: AATACAGAGGAAGAGCGATTCATGGCATCAAACCC; Reverse primer: GCTCTTCCGTCTGTATTCGAAGGGCATCCATCTCTCC) with Q5 polymerase (New England Biolabs, Ipswitch, MA). The neonatal construct differed from the adult by inclusion of the neonatal exon 6N instead of the adult exon. All constructs were verified by Sanger sequencing of the promoter through to the polyadenylation signal, inclusive.

HEK293T cells (ATCC, Manassas, VA) were stably transfected with the β1 and β2 sodium channel subunits under puromycin selection to generate a stable cell line using previously established methods\textsuperscript{11}. Cells were maintained at passages 5-15 in DMEM media supplemented with 1% Pen/Strep, 10% FBS, and puromycin (3 μg/mL). The HEK293Tβ1/β2 cell line was transiently transfected using SuperFect reagent (Qiagen, Germantown, MD) with 2 μg of WT or mutant Na\textsubscript{v}1.2 plasmid along with 0.25 μg of a second plasmid (pEGFP-IRES-SCN2B) for use as an additional transfection marker. After 24-48 h, transfected cells were harvested with trypsin and plated on poly-D-lysine (Sigma-Aldrich, St. Louis, MO) coated coverslips prior to recording. Only fluorescent cells were selected for whole-cell patch clamp recording.

Electrophysiology
Whole-cell patch-clamp recordings were performed at room temperature (22-23°C). Borosilicate glass pipettes were pulled with a P-1000 (Sutter Instruments, Novato, CA), with resistances of 1-2.5 MOhm. External solution contained (in mmol/L) 140 NaCl, 10 HEPES, 4 KCl, 1 MgCl₂, 1.8 CaCl₂, 10 dextrose, pH 7.35 adjusted with NaOH, osmolarity 310 mOsm. Internal solution contained (in mmol/L) 10 NaF, 105 CsF, 20 CsCl, 2 EGTA, 10 HEPES, 10 dextrose, pH 7.35 adjusted with CsOH, osmolarity 300 mOsm. For measurement of resurgent current, 200 µM β4 peptide was included in the internal solution. Recordings were acquired with an Axopatch 200B amplifier (Molecular Devices, Sunnyvale, CA) at 50 kHz and filtered at 5 kHz. Leak subtraction was performed with a P/4 protocol. Fast and slow capacitive currents were compensated. After achieving the whole-cell configuration, recordings began after 10 minutes to allow for equilibration of cell contents with the internal solution. Series resistance was compensated 80-90%, and cells with unstable series resistance or series resistance >8 MOhms were discarded from further analysis.

Protocols for activation, inactivation, recovery from inactivation, and resurgent current are depicted in the figures. To measure residual current after high-frequency pulses, cells were held at -120 mV and depolarized to 0 mV for 5 ms for 300 pulses at the indicated frequency. The residual current was calculated as the ratio of the 300th pulse to the 1st pulse. Resurgent current was assessed by first depolarizing the cell to +30 mV, followed by repolarization steps at the indicated voltages. Persistent current was calculated as the average current of the last 10 ms of a 200 ms depolarizing pulse to 0 mV, normalized to the peak current from a TTX-subtracted record.

Data Analysis

Analysis of electrophysiological data was performed with ClampFit (Molecular Devices), Microsoft Excel, MatLab (Mathworks, Natick, MA), and GraphPad Prism (San Diego, CA). All data points are represented as mean ± SEM, and n is the sample size. Current densities were
calculated by dividing peak currents at each potential by the membrane capacitance obtained during recording. Conductance was calculated using the equation $G = \frac{I}{V - E_{rev}}$, where $E_{rev}$ is the calculated sodium reversal potential. Activation and inactivation $V_{1/2}$ values were obtained by fitting the normalized conductance (activation) or the normalized current (inactivation) to a Boltzmann equation: $1/(1+\exp[(V - V_{1/2})/k])$, where $V_{1/2}$ is the half-activation voltage and $k$ is the slope factor. Inactivation time-course was estimated by fitting a single-component exponential curve to the decay portion of the sodium current using ClampFit. Recovery from inactivation was fit with a biexponential curve using Prism. The data distribution was assessed for normality with a Shapiro-Wilk test. If the data were normally distributed, a parametric test (t-test) was used to assess significance; if not, a nonparametric test was used (Mann-Whitney U-test). Statistical significance was set at $P<0.05$. When assessing three or more groups (as in the carbamazepine experiment), the data were analyzed with a repeated measures ANOVA with Dunnett’s multiple comparisons post-hoc test, comparing each drug response to the control condition.

**Reagents**

Tetrodotoxin (TTX; Tocris Bioscience, Minneapolis, MN) was prepared as a 1 mM stock solution in water, then diluted to 500 nM in the external solution. Carbamazepine (Sigma) was prepared as a 250 mM stock solution in DMSO and diluted to the indicated concentration in the external solution. A β4 peptide (KKLITFILKKTREK-OH), generously supplied by Dr. Chris Ahern at the University of Iowa, was diluted in the internal solution to a final concentration of 200 µM and used immediately or frozen in aliquots.

**Molecular Modeling**

A structure of the C-Terminal domain of human Na\textsubscript{v}1.2 determined by X-ray crystallography at 3.02 Angstrom resolution in complex with calmodulin and FGF13 was obtained from chain B of
PDB code 4JPZ. The Met-1879 residue was changed to Thr \textit{in silico} using UCSF Chimera (RBVI, San Francisco, CA), with the highest probability rotamer selected. This M1879T structure and the original structure (WT) were then energy minimized using 1000 steepest descent and 10 conjugate gradient steps. Contacts of non-backbone residues with either Met-1879 or Thr-1879 were identified using Chimera with default parameters.
RESULTS

Case Report

An infant boy was evaluated for a seizure disorder accompanied by mild global developmental delay with onset at age two months. He had a normal birth history, and no family history of seizures or epilepsy. The child initially came to medical attention for an apneic event, which was diagnosed as reflux. EEG and brain MRI were performed which were normal. Events recurred and he was referred to Lurie Children’s and diagnosed with tonic seizures accompanied by apneic spells and cyanosis. Neurological exam was notable for low axial and appendicular muscle tone. He was treated with levetiracetam, pyridoxine, and topiramate, yet continued to have daily seizures. Following each acute loading dose of intravenous fosphenytoin he became seizure free for two days, but then seizures recurred. Transition to oral phenytoin maintained seizure freedom. Genetic testing revealed a de novo SCN2A variant (c.5636T>C) predicting a novel missense mutation (p.Met1879Thr, M1879T) in the Na_v1.2 voltage-gated sodium channel. On follow-up, there had been difficulty maintaining adequate phenytoin levels, and he was transitioned to carbamazepine monotherapy with continued seizure control. At last follow up after 2 years old, he has developmental delay and hyperactivity with autistic features. He had minimal receptive and expressive language, can feed himself, and can run with an ataxic gait.

Functional consequences of SCN2A-M1879T

We investigated the functional effect of the M1879T mutation using recombinant human Na_v1.2 expressed in a heterologous cell line (HEK293T) stably expressing the human β1 and β2 subunits. Representative voltage-dependent currents recorded from WT and M1879T expressing cells are depicted in Figure 1A and summary data for all functional properties are presented in Table 1. The peak current density was not significantly different between WT and M1879T channels (Figure 1B). However, the time-course of inactivation was significantly
slower for M1879T compared to WT channels (Figure 1C, upper). A voltage ramp protocol evoked a pronounced aberrant current in cells expressing M1879T but not in WT expressing cells (Figure 1C, lower). Inactivation time constants reveal a significant impairment of M1879T inactivation compared to WT across the range of tested voltages (Figure 1D). M1879T mutant channels did not exhibit a significant difference in persistent sodium current measured as a percentage of peak current. These findings are consistent with impaired fast inactivation for the mutant channel that predicts greater sodium conductance over time following channel activation.

We compared the voltage-dependence of channel activation and steady-state inactivation between M1879T and WT channels. The voltage dependence of activation was not different between M1879T and WT channels (Figure 2A). By contrast, cells expressing M1879T exhibited a significantly depolarized steady-state inactivation curve compared to WT expressing cells (Figure 2B). These results are also consistent with altered fast inactivation and predict greater sodium conductance by mutant channels evoked by membrane depolarizations within the physiological range.

Recovery from inactivation, assessed using a two-pulse protocol, followed a biexponential time course and was not significantly different between M1879T and WT channels (Figure 2C). Similarly, sodium channel availability during depolarizing pulse trains at different frequencies (10, 25, 50, and 100 Hz) were not significantly different between mutant and WT channels (Figure 2D). These results suggest that M1879T selectively affects the kinetics of onset and voltage-dependence of channel inactivation.

SCN2A undergoes developmentally regulated alternative mRNA splicing that leads to incorporation of an alternate exon encoding a portion of the domain I voltage-sensor domain (S3
and S4 helices). Because SCN2A variants associated with early onset epilepsy may exhibit more severe functional consequences in the splice variant expressed preferentially during early development, we tested whether the substitution of the neonatal exon would affect the properties of the M1879T mutant channel. In this case, none of the key functional properties (Supplemental Figure S1) were significantly different between the adult and neonatal isoforms of the M1879T channel.

**M1879T channels exhibit enhanced resurgent current**

We next compared the level of resurgent current between WT and M1879T channels. These experiments were motivated by a prior report indicating that the epilepsy-associated mutation SCN2A-R1882Q affecting a nearby residue had greater resurgent current than WT channels. We recorded resurgent current in WT and M1879T expressing cells elicited by the voltage protocol shown in Figure 3A (top) with the β4 peptide in the internal solution. M1879T channels (Figure 3A, bottom) exhibited larger resurgent currents than WT channels (Figure 3A, middle). This difference was evident across several tested voltages with comparisons made using either current density (Figure 3B) or the level of resurgent current measured as a percentage of the peak current elicited at -10 mV (Figure 3C). Enhanced resurgent current exhibited by M1879T channels may contribute to the gain of sodium conductance conferred by this mutation.

**Effect of carbamazepine on M1879T channels**

Because carbamazepine (CBZ) was effective as monotherapy in the reported case, we examined the effects of this drug on M1879T channels (adult splice isoform). As shown in Figure 4A, application of 100 µM and 300 µM CBZ caused a dose-dependent hyperpolarizing shift in steady-state inactivation (control [no drug]: $V_{1/2} = -48.5$; 100 µM CBZ: $V_{1/2} = -52.0$; 300 µM CBZ: $V_{1/2} = -55.8$; n=6). By comparing each treated cell to its own control value, we
determined that 100 μM and 300 μM CBZ caused 3.5 ± 0.7 mV and 8.5 ± 0.7 mV hyperpolarizing shifts in steady-state inactivation $V_{1/2}$, respectively (Figure 4B). Vehicle (DMSO) treatment did not cause a significant shift in steady-state inactivation (data not shown). Furthermore, CBZ reduced the aberrant ramp current exhibited by M1879T channels (Figure 4C). Finally, CBZ was associated with a significantly lower degree of channel availability after high-frequency pulses at 100 Hz (fractional availability after 300th pulse: control: 0.61; 100 μM CBZ: 0.49; 300 μM CBZ: 0.32, n=5; p=0.0105 for control vs. 100 μM CBZ and p=0.0014 for control vs. 300 μM CBZ), but not at lower pulsing frequencies (Figure 4D). The partial normalization of voltage-dependence of inactivation coupled with use-dependent block of the mutant channel correlate with the clinical efficacy of CBZ in the reported case.

We also assessed whether CBZ treatment affects resurgent current. Cells expressing M1879T were treated with either 300 μM CBZ or DMSO vehicle. Cells treated with DMSO only (Figure 5A, left) exhibited a time-dependent rise in resurgent current, likely related to the time-dependent diffusion of the β4 peptide into the intracellular compartment seen in control solution (data not shown). In contrast, cells treated with CBZ showed lower resurgent current levels compared to the control condition (Figure 5A, B). Specifically, DMSO-treated cells exhibited a 22.1 ± 4.6% (n=7) rise in maximal resurgent current density compared to control, while CBZ-treated cells had a 21.2 ± 3.1% (n=7) fall compared to the control condition (Figure 5C). Because CBZ affects peak current, we considered the possibility that reduced resurgent current merely reflects a proportional reduction in the total current. Indeed, 300 μM CBZ treatment caused a significant change in peak current compared to DMSO treatment (Figure 6A). When this difference was taken into account by examining the maximal resurgent current as a percentage of the peak current, there remained a significant difference between the DMSO-treated and CBZ-treated cells (Figure 6B). Taken together, these data indicate that 300 μM
CBZ likely attenuates resurgent current independent of its effect on peak current, but this effect is modest.
DISCUSSION

Our study investigated a de novo SCN2A coding sequence variant (p.M1879T) associated with infantile-onset epilepsy. The child we report exhibited frequent tonic seizures complicated by apnea unresponsive to levetiracetam and topiramate then subsequently had a dramatic response to the sodium channel blockers phenytoin and later carbamazepine. Initially the variant was categorized as a variant of uncertain significance (VUS), but electrophysiological evaluation of the variant sodium channel revealed severely impaired inactivation gating consistent with a gain-of-function. Specifically, we observed a substantially depolarized voltage-dependence of inactivation, slower time course of inactivation, and enhanced resurgent current. Unlike other SCN2A variants associated with early-onset epilepsy, expression of the variant in the neonatal splice variant of the channel was not associated with greater dysfunction.13 Carbamazepine partially normalized the voltage-dependent inactivation of the mutant channel, dampened resurgent current, and exhibited potent frequency-dependent block of the mutant channel. Therefore, our study demonstrates concordance of in vitro pharmacology using heterologous cells with the drug response observed clinically for the affected child.

The novel missense mutation we report in this paper affects residue Met-1879 located in the distal portion of the intracellular carboxyl-terminal domain (CTD), upstream of a conserved IQ domain necessary for calmodulin binding.15–17 This methionine residue is absolutely conserved in the mammalian voltage-gated sodium channel family. Variants affecting orthologous sodium channels predicting the same methionine to threonine amino acid substitution occur at corresponding positions in the cardiac sodium channel (Na_v1.5, M1875T) associated with familial atrial fibrillation,18 and in a peripheral nerve sodium channel (Na_v1.7, M1870T) associated with painful diabetic peripheral neuropathy.19 Both orthologous mutations exhibited similar biophysical effects as SCN2A-M1879T in heterologous cells including a depolarizing shift in the voltage-dependent inactivation and slowed inactivation kinetics without affecting voltage-
dependent activation or persistent current. These results along with our findings implicate Met-1879 as important for inactivation properties, and mutation to threonine appears to destabilize the inactivated state of the channel.

Other epilepsy-associated mutations have been identified in the Na\textsubscript{V}1.2 CTD most notably R1882Q, which causes early-onset epilepsy of varying severity and drug-responsiveness. The R1882Q channel exhibits a depolarized voltage-dependence of inactivation, as well as an increase in non-inactivating persistent current compared to wild-type channels, an attribute we did not observe for the M1879T channel. This combination of functional anomalies is predicted to promote greater neuronal excitability.\cite{20}

The molecular basis for channel dysfunction associated with the M1879T mutation can be considered in the context of recent advances in the structural biology of sodium channels. In the past few years, there has been an explosion of available structures for eukaryotic sodium channels, including human Na\textsubscript{V}1.2.\cite{21} Unfortunately, the intracellular regions including the CTD are poorly resolved or missing in most of these structures except in the full-length sodium channel from the American cockroach (Na\textsubscript{VPas}).\cite{22} Fortunately, there are structural data available for the isolated Na\textsubscript{V}1.2 CTD in complex with calmodulin and FGF13.\cite{12} In this structure, Met-1879 resides within an alpha-helix that forms a helix-loop-helix motif neighboring the IQ domain needed for calmodulin binding. The proximity of this residue to the base of the fourth voltage-sensing domain provides a plausible explanation for how the M1879T mutation might affect inactivation driven by this domain.\cite{23} In this structure, the side chain of Met-1879 projects outward to a nearby helix in the CTD where it forms contacts with a network of side chains belonging to nearby residues (Figure 7A). Molecular modeling suggests that the M1879T variant, with its smaller side chain, eliminates several of these intramolecular contacts that may stabilize inactivation (Figure 7B).
An understudied functional effect of SCN2A mutations is resurgent current, and only two variants (R853Q, R1882Q) have been investigated previously for this phenomenon in heterologous cells.\textsuperscript{14} R853Q channels exhibit less resurgent current compared to WT channels, whereas R1882Q has a much larger resurgent current compared, similar to what we observed with M1879T. However, the impact of resurgent current on promoting epileptic activity is unclear. Resurgent currents have been demonstrated for other sodium channelopathies, including those implicated in pain, myotonia, long-QT syndrome, and SCN8A-related epilepsy.\textsuperscript{24–26}

We examined the effect of carbamazepine on resurgent current to determine if suppression of this anomalous channel activity might explain the antiepileptic effects observed in this patient. Although high CBZ concentration (300 \(\mu M\)) did significantly suppress resurgent current, the reduction we observed correlated with an overall reduction in peak current. When resurgent current was normalized to peak current, the effect of carbamazepine appeared modest. These experimental findings suggested that the principal effect of carbamazepine on reducing seizures associated with the M1879T variant more likely relates to changes in voltage-dependent inactivation and channel inhibition at high-frequency stimulation rather than attenuation of resurgent current.

Suppression of resurgent current by other agents has also been demonstrated. The endogenous cannabinoid anandamide inhibits resurgent current without affecting transient current,\textsuperscript{27} whereas PRX-330, a novel anti-epileptic drug candidate, inhibits both persistent and resurgent currents in a mouse model of SCN8A encephalopathy.\textsuperscript{28} Cannabidiol (CBD), a recently approved anti-epileptic drug for the treatment of Dravet and Lennox-Gastaut syndromes, also inhibits resurgent current more than transient current associated with two epilepsy-associated SCN8A variants (L1331V, N1768D).\textsuperscript{25} Further investigations of resurgent current pharmacology are warranted.
In summary, our study illustrates that functional and pharmacological investigations of $SCN2A$ variants in heterologous cells has value in defining genotype-phenotype correlations, demonstrating molecular mechanisms of disease and drug responses, and contributing to our knowledge of structure-functional relationships for the broader voltage-gated sodium channel family.
ACKNOWLEDGEMENTS
The authors sincerely thank the patient and his family for their inclusion in this study. This work was supported by National Institute of Neurological Disorders and Stroke grants R25-NS070695 (S.K.A.) and U54-NS108874 (A.L.G.), and a generous gift from the Davee Foundation (A.L.G.).

CONFLICT OF INTEREST
Adney, DeKeyser, Abramova, and Thompson declare no conflicts of interest with the work described herein. Millichap reports personal fees from American Academy of Neurology, personal fees from Up-To-Date, grants from UCB Pharma, grants and personal fees from Mallinkrodt, personal fees from Esai, grants and personal fees from Xenon, personal fees from Biocare, personal fees from Ionis, personal fees from Greenwich, personal fees from Sunovion, personal fees from Upsher-Smith, grants from NIH, grants from Citizens United for Research in Epilepsy, personal fees from Praxis, outside the submitted work. George reports personal fees from Amgen, Inc., grants from Praxis Precision Medicines, Inc., outside the submitted work.

AUTHORS’ CONTRIBUTIONS
The study was conceived by SKA, JMM and ALG. Experiments were designed by SKA and ALG with guidance from CHT. Experiments were performed and data analyzed by SKA. JMD, CHT, and TA performed mutagenesis and development of cell lines. SKA and ALG wrote the manuscript with input from all co-authors.
REFERENCES


   1348;DOI:10.1073/pnas.0910383107

   2014;5:4896;DOI:10.1038/ncomms5896

13. Thompson CH, Ben-Shalom R, Bender KJ, George AL. Alternative splicing potentiates
   2020;152(3);DOI:10.1085/jgp.201912442

   Novo SCN2A epilepsy mutations. eNeuro 2019;6(5);DOI:10.1523/ENEURO.0141-
   19.2019

   channel (VDSC) with calmodulin: Does VDSC acquire calmodulin-mediated Ca\(^{2+}\)-

   Biol. Chem. 2004;279(43):45004–45012;DOI:10.1074/jbc.M407286200

17. Theoharis NT, Sorensen BR, Theisen-Toupal J, Shea MA. The neuronal voltage-
   dependent sodium channel type II IQ motif lowers the calcium affinity of the C-domain of


19. Blesneac I, Themistocleous AC, Fratter C, et al. Rare Na\(_V\)1.7 variants associated with
   painful diabetic peripheral neuropathy. Pain 2018;159(3):469–
   480;DOI:10.1097/j.pain.0000000000001116

   functional separation in mild familial and severe de novo forms of SCN2A epilepsy. Proc.


27. Theile JW, Cummins TR. Inhibition of Nav\(\beta\)4 peptide-mediated resurgent sodium currents in Na\(_{v}1.7\) channels by carbamazepine, riluzole, and anandamide. Mol. Pharmacol. 2011;80(4):724–734;DOI:10.1124/mol.111.072751

FIGURE LEGENDS

Figure 1.  M1879T mutation alters NaV1.2 inactivation kinetics. (A) Representative current recordings from WT and M1879T NaV1.2 obtained using the voltage protocol shown in Figure 2A (inset). (B) Current density-voltage plot for WT (n=14) and M1879T (n=14) channels. (C) Top, average of six TTX-subtracted recorded at 0 mV and normalized to peak current to highlight inactivation time-course of WT (black) and M1879T (blue). Bottom, average currents for WT (black, average of 5) and M1879T (blue, average of 6) elicited using the voltage ramp protocol shown below. Traces were normalized to peak current measured at 0 mV. (D) Voltage-dependence of inactivation time constants determined from single-component exponential curve fits to the current decay. n=14 for WT and n=14 for M1879T, *p<0.05 by Mann-Whitney U test.

Figure 2.  M1879T affects voltage-dependence of inactivation. (A) Voltage-dependence of activation of WT (n=14) and M1879T (n=14) channels determined using the voltage protocol shown as an inset. There was no difference in activation V1/2 between WT and M1879T (p=0.51 by Mann-Whitney U test). (B) Voltage-dependence of inactivation of WT (n=18) and M1879T (n=25) channels (voltage protocol shown as an inset). There was a significant depolarizing shift in inactivation V1/2 (p<0.0001 by Mann-Whitney U test). (C) Time course of recovery from inactivation after 100 ms depolarization (protocol shown as inset) comparing WT (n=10) and M1879T (n=10). (D) Plot of residual current (comparing 300th pulse to 1st pulse) after repetitive pulsing to 0 mV at the indicated frequency (n=7 for WT and n=7 for M1879T). There were no significant differences between WT and M1879T at any frequency (p>0.05 by Mann-Whitney U test).
**Figure 3.** M1879T exhibits enhanced resurgent current. (A) Top, voltage protocol for eliciting resurgent current. Middle (WT) and bottom (M1879T) panels show representative current traces using protocol above (10 mV voltage steps are illustrated). The blue trace represents the peak resurgent current elicited at -20 mV. (B) Voltage dependence of resurgent current density for WT and M1879T (*, p<0.05 by Mann-Whitney U test). (C) Plot of resurgent current expressed as % of peak transient current for WT and M1879T (*, p<0.05 by Mann-Whitney U test).

**Figure 4.** Effects of carbamazepine on M1879T channels. (A) Carbamazepine (CBZ) induces a hyperpolarizing shift of the voltage-dependence of inactivation (n=6). (B) Plot of change in inactivation V_{1/2} in response to 100 µM and 300 µM carbamazepine (n=6; *, p<0.05 by paired t-test). (C) Ramp current determined in the absence (control) or presence of 100 µM CBZ (red trace) and 300 µM CBZ (blue trace). (D) Plot of residual current (comparing 300^{th} pulse to 1^{st} pulse) after 0 mV pulses at the indicated frequency. At 100 Hz, there was a significant difference in residual current in the presence of 100 µM and 300 µM CBZ compared to control conditions (one-way ANOVA with repeated measures and Dunnett’s post-hoc test, *p < 0.05 for 100 µM vs. control; **p < 0.05 for 300 µM vs. CBZ; n=5).

**Figure 5.** Effect of carbamazepine on resurgent current. (A) Representative M1879T resurgent current traces before (top) and after DMSO (bottom) treatment. (B) Representative M1879T resurgent current before (top) and after CBZ (bottom) treatment. (C) Percent change in maximum resurgent current density, comparing DMSO and CBZ (n = 7; *, p<0.0001 by unpaired t test).
**Figure 6.** Comparison of carbamazepine effects on M1879T peak transient and resurgent current. (A) Percent change in peak transient current (DMSO: -4.5 ± 1.3% vs. CBZ: -20.7 ± 1.3%; n=7 both groups; *, p<0.0001 by unpaired t test). (B) Percent change in resurgent current (as percent of peak transient current; DMSO: 28.2 ± 5.9% vs. CBZ: 4.1 ± 6.8% of peak, n=7 for both groups; **, p=0.02 by unpaired t test).

**Fig. 7.** Molecular modeling of Met-1879 and Thr-1879 contacts in Na\(\sqrt{v}\)1.2 C-terminal domain. (A) Ribbon diagram of WT channel showing specific contacts between Met-1879 and interacting residues (red lines). (B) Ribbon diagram of M1879T channel showing specific contacts between Thr-1879 and interacting residues (red lines).
Table 1. Summary of functional properties for WT and M1879T channels

<table>
<thead>
<tr>
<th></th>
<th>WT (n)</th>
<th>M1879T (n)</th>
<th>M1879T-neonatal (n)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Peak current density (pA/pF)</td>
<td>-972 ± 35 (14)</td>
<td>-908 ± 163 (14)</td>
<td>-654 ± 125 (12)</td>
</tr>
<tr>
<td>Inactivation time constant</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(∝, ms) 0 mV</td>
<td>0.36 ± 0.04 (14)</td>
<td>0.68 ± 0.04* (14)</td>
<td>0.69 ± 0.05 (12)</td>
</tr>
<tr>
<td>Activation voltage-dependence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(V_{1/2}) (mV)</td>
<td>-29.2 ± 1.7 (14)</td>
<td>-28.2 ± 1.8 (14)</td>
<td>-27.7 ± 1.2 (14)</td>
</tr>
<tr>
<td>Slope factor (k)</td>
<td>4.8 ± 0.5 (14)</td>
<td>4.5 ± 0.4 (14)</td>
<td>4.8 ± 0.4 (14)</td>
</tr>
<tr>
<td>Inactivation voltage-dependence</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(V_{1/2}) (mV)</td>
<td>-66.3 ± 1.1 (18)</td>
<td>-53.8 ± 1.1* (25)</td>
<td>-50.3 ± 1.4 (15)</td>
</tr>
<tr>
<td>Slope factor (k)</td>
<td>-6.1 ± 0.2 (18)</td>
<td>-7.4 ± 0.3* (25)</td>
<td>-7.8 ± 0.3 (15)</td>
</tr>
<tr>
<td>Recovery from inactivation</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(\tau_{\text{slow}}) (ms)</td>
<td>154 ± 88 (10)</td>
<td>139 ± 35 (10)</td>
<td>132 ± 28 (11)</td>
</tr>
<tr>
<td>(\tau_{\text{fast}}) (ms)</td>
<td>2.18 ± 0.30 (10)</td>
<td>2.48 ± 0.32 (10)</td>
<td>2.96 ± 0.44 (11)</td>
</tr>
<tr>
<td>% fast component</td>
<td>77.7 ± 1.8 (10)</td>
<td>76.7 ± 4.4 (10)</td>
<td>78.3 ± 3.1 (11)</td>
</tr>
<tr>
<td>Persistent Current (% of peak)</td>
<td>0.33 ± 0.05 (9)</td>
<td>0.21 ± 0.04 (9)</td>
<td>0.47 ± 0.11 (8)</td>
</tr>
</tbody>
</table>
Figure 1

A

WT

M1879T

6 nA
5 ms

B

Current Density (pA/pF)

Voltage (mV)

WS

M1879T

C

50% \(I_{Na}\)

2 ms

WT

M1879T

1% peak

10 mV

450 ms (0.2 mV/ms)

0 mV

D

Time Constant (ms)

Voltage (mV)

WS

M1879T
Figure 2

(A) Normalized Conductance vs. Voltage (mV) for WT and M1879T.

(B) Normalized Current vs. Voltage (mV) for WT and M1879T.

(C) Fractional Recovery vs. Recovery Interval (ms) for WT and M1879T.

(D) Normalized Current vs. Pulse Frequency (Hz) for WT and M1879T.
Figure 3

A

+30 mV, 20 ms
50 ms
+5 mV
-60 mV
-120 mV

WT

M1879T

B

Resurgent Current Density (pA/pF)

Voltage (mV)

WT

M1879T

C

Resurgent Current (% of Peak Current)

Voltage (mV)

WT

M1879T
Figure 5

A  
Control  

B  
Control  

DMSO  

CBZ  

C  

% Change in Max Resurgent Current Density  

<table>
<thead>
<tr>
<th>DMSO</th>
<th>CBZ</th>
</tr>
</thead>
<tbody>
<tr>
<td>-20</td>
<td>-10</td>
</tr>
<tr>
<td>-10</td>
<td>-5</td>
</tr>
<tr>
<td>0</td>
<td>5</td>
</tr>
<tr>
<td>10</td>
<td>15</td>
</tr>
<tr>
<td>20</td>
<td>25</td>
</tr>
</tbody>
</table>

* Indicates significant difference.
Figure 6

A

B

% Change in Peak Current

% Change in Resurgent Current (% of Peak)

DMSO  CBZ

DMSO  CBZ

*  **
Figure 7

A

B